Lawrence Karsh, MD, FACS

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    FKD
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Spouse or Partner
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Swan Valley Medical
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Vaxiion
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Investment Interest (Oncology)
    Ineligible company: 
    3D Biopsy
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Nymox
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Precision Biopsy
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    OPKO
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Precision Med
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Augmenix
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myriad Genetics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer